董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael E. Severino | 男 | Independent Director | 59 | 未披露 | 未持股 | 2025-12-31 |
| Juan Andres | 男 | Independent Director | 60 | 7.71万 | 未持股 | 2025-12-31 |
| Gregory Lucier | 男 | Director | 61 | 未披露 | 未持股 | 2025-12-31 |
| Louise Makin | 女 | Independent Director | 64 | 未披露 | 未持股 | 2025-12-31 |
| Greg Summe | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-31 |
| John Carethers | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-31 |
| Joseph Massaro | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-31 |
| Lan Kang | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-31 |
| Mala Murthy | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-31 |
| Emmanuel Ligner | 男 | Director, President and Chief Executive Officer | 55 | 未披露 | 未持股 | 2025-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christophe Couturier | 男 | Executive Vice President, AMEA | 59 | 未披露 | 未持股 | 2025-12-31 |
| James Bramwell | 男 | Executive Vice President, Sales and Customer Excellence | 58 | 未披露 | 未持股 | 2025-12-31 |
| Emmanuel Ligner | 男 | Director, President and Chief Executive Officer | 55 | 未披露 | 未持股 | 2025-12-31 |
| Brittany Hankamer | -- | Executive Vice President and Chief Human Resources Officer | -- | 未披露 | 未持股 | 2025-12-31 |
| Steven W. Eck | -- | Senior Vice President and Chief Accounting Officer | -- | 未披露 | 未持股 | 2025-12-31 |
| R. Brent Jones | -- | Executive Vice President and Chief Financial Officer | -- | 未披露 | 未持股 | 2025-12-31 |
| Claudius Sokenu | -- | Executive Vice President, Chief Legal Officer and Chief Compliance Officer and Corporate Secretary | -- | 未披露 | 未持股 | 2025-12-31 |
| Kitty Sahin | -- | Executive Vice President, Strategy and Corporate Development | -- | 未披露 | 未持股 | 2025-12-31 |
| Benoit Gourdier | -- | Executive Vice President, Bioscience Production | -- | 未披露 | 未持股 | 2025-12-31 |
董事简历
中英对照 | 中文 | 英文- Michael E. Severino
-
Michael E. Severino是Avantor, Inc.的副董事长兼总裁，负责研发和企业战略办公室。他曾于2014年至2018年担任执行副总裁、研发和首席科学官。Severino博士曾于2012年至2014年在安进公司担任全球发展高级副总裁兼公司首席医疗官，2010年至2012年担任全球发展副总裁，2007年至2012年担任普通医学和炎症全球临床发展副总裁兼治疗领域主管。他于2014年加入Avantor, Inc.，并于2014年6月首次被任命为艾伯维公司高管。Severino博士还担任Avantor, Inc.的董事会成员。
Michael E. Severino is AbbVie's Vice Chairman and President, responsible for research and development and the corporate strategy office. He served as Executive Vice President, Research and Development and Chief Scientific Officer from 2014 to 2018. Dr. Severino served at Amgen Inc. as Senior Vice President, Global Development and Corporate Chief Medical Officer from 2012 to 2014 as Vice President, Global Development from 2010 to 2012 and as Vice President, Therapeutic Area Head, General Medicine and Inflammation Global Clinical Development from 2007 to 2012. He joined AbbVie in 2014 and was first appointed as an AbbVie corporate officer in June 2014. Dr. Severino also serves on the board of Avantor, Inc. - Michael E. Severino是Avantor, Inc.的副董事长兼总裁，负责研发和企业战略办公室。他曾于2014年至2018年担任执行副总裁、研发和首席科学官。Severino博士曾于2012年至2014年在安进公司担任全球发展高级副总裁兼公司首席医疗官，2010年至2012年担任全球发展副总裁，2007年至2012年担任普通医学和炎症全球临床发展副总裁兼治疗领域主管。他于2014年加入Avantor, Inc.，并于2014年6月首次被任命为艾伯维公司高管。Severino博士还担任Avantor, Inc.的董事会成员。
- Michael E. Severino is AbbVie's Vice Chairman and President, responsible for research and development and the corporate strategy office. He served as Executive Vice President, Research and Development and Chief Scientific Officer from 2014 to 2018. Dr. Severino served at Amgen Inc. as Senior Vice President, Global Development and Corporate Chief Medical Officer from 2012 to 2014 as Vice President, Global Development from 2010 to 2012 and as Vice President, Therapeutic Area Head, General Medicine and Inflammation Global Clinical Development from 2007 to 2012. He joined AbbVie in 2014 and was first appointed as an AbbVie corporate officer in June 2014. Dr. Severino also serves on the board of Avantor, Inc.
- Juan Andres
-
Juan Andres，Novartis AG（2005年至2017年）担任各种职责，包括技术运营制造和供应链全球总监、质量全球总监和技术研发全球总监。Eli Lilly和Company（1987年至2005年）担任各种制造、生产和质量职务，包括制药副总裁。自2019年12月起担任伊芙洛生物科学公司董事会成员，自2019年9月起担任Avantor公司董事会成员。阿尔卡尔大学在西班牙，获得药学学位。
Juan Andres,Novartis AG from 2005 to 2017 in various roles of increasing responsibility, including Global Head of Technical Operations Manufacturing and Supply Chain, Global Head of Quality, and Global Head of Technical Research and Development.Eli Lilly and Company from 1987 to 2005 in various manufacturing, production, and quality roles, including Vice President, Pharmaceutical Manufacturing.Member of the Board of Directors of Evelo Biosciences, Inc. since December 2019 and of Avantor, Inc. since September 2019.Universidad de Alcalá in Spain, degree in pharmacy. - Juan Andres，Novartis AG（2005年至2017年）担任各种职责，包括技术运营制造和供应链全球总监、质量全球总监和技术研发全球总监。Eli Lilly和Company（1987年至2005年）担任各种制造、生产和质量职务，包括制药副总裁。自2019年12月起担任伊芙洛生物科学公司董事会成员，自2019年9月起担任Avantor公司董事会成员。阿尔卡尔大学在西班牙，获得药学学位。
- Juan Andres,Novartis AG from 2005 to 2017 in various roles of increasing responsibility, including Global Head of Technical Operations Manufacturing and Supply Chain, Global Head of Quality, and Global Head of Technical Research and Development.Eli Lilly and Company from 1987 to 2005 in various manufacturing, production, and quality roles, including Vice President, Pharmaceutical Manufacturing.Member of the Board of Directors of Evelo Biosciences, Inc. since December 2019 and of Avantor, Inc. since September 2019.Universidad de Alcalá in Spain, degree in pharmacy.
- Gregory Lucier
-
Gregory Lucier自2020年6月以来一直担任我们的董事会成员。Lucier先生自2019年4月起担任Corza Health，Inc.（一家私人控股公司，专注于收购公司和资产，作为建立市场领先的梦百合业务战略的一部分）的首席执行官。在此之前，他曾于2015年6月至2018年12月担任上市医疗设备公司Nuvasive，Inc.的首席执行官。在加入NuVasive之前，Lucier先生于2003年5月至2014年2月担任Life Technologies Corporation（前身为Invitrogen Corporation，一家上市的全球生物技术公司）的董事长兼首席执行官，该公司于2014年2月被赛默飞世尔科技公司收购。在此之前，Lucier先生是通用电气公司的一名公司官员，他在该公司担任过各种领导职务。Lucier先生是Nuvasive，Inc.公司（一家上市医疗设备公司）和Epic Sciences公司（一家私营生物技术公司）的董事会主席，并曾担任Catalent，Inc.公司（一家上市制药公司）的董事，自2015年4月起，他曾于2003年5月至2014年2月任职于Life Technologies Corporation的董事会，该公司是一家上市医疗设备公司，2009年8月至2015年3月被出售给Becton Dickinson和Invuity，Inc.从2014年10月到2018年10月出售给Stryker。Lucier先生在宾夕法尼亚州立大学（Pennsylvania State University）获得工业工程学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Gregory Lucier has served as a member of our board of directors since June 2020. Mr. Lucier has served as the Chief Executive Officer of Corza Health, Inc., a privately-held company focused on acquiring companies and assets as part of a strategy to build a market-leading healthcare business, since April 2019. Prior to that, he served as Chief Executive Officer of NuVasive, Inc., a publicly-traded medical device company, from June 2015 to December 2018. Before joining Nuvasive, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation formerly Invitrogen Corporation, a publicly-traded global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is Chairman of the boards of directors of Nuvasive, Inc., a publicly traded medical device company, and Epic Sciences, a privately-held biotechnology company, and has served as a director of Catalent, Inc., a publicly-traded pharmaceutical company, since April 2015 and previously served on the boards of directors of Life Technologies Corporation from May 2003 to February 2014 of CareFusion Corporation, a publicly-traded medical device company, from August 2009 until its sale to Becton Dickinson in March 2015 and of Invuity, Inc. from October 2014 until its sale to Stryker in October 2018. Mr. Lucier received his B.S. in Industrial Engineering from Pennsylvania State University and his M.B.A. from Harvard Business School. - Gregory Lucier自2020年6月以来一直担任我们的董事会成员。Lucier先生自2019年4月起担任Corza Health，Inc.（一家私人控股公司，专注于收购公司和资产，作为建立市场领先的梦百合业务战略的一部分）的首席执行官。在此之前，他曾于2015年6月至2018年12月担任上市医疗设备公司Nuvasive，Inc.的首席执行官。在加入NuVasive之前，Lucier先生于2003年5月至2014年2月担任Life Technologies Corporation（前身为Invitrogen Corporation，一家上市的全球生物技术公司）的董事长兼首席执行官，该公司于2014年2月被赛默飞世尔科技公司收购。在此之前，Lucier先生是通用电气公司的一名公司官员，他在该公司担任过各种领导职务。Lucier先生是Nuvasive，Inc.公司（一家上市医疗设备公司）和Epic Sciences公司（一家私营生物技术公司）的董事会主席，并曾担任Catalent，Inc.公司（一家上市制药公司）的董事，自2015年4月起，他曾于2003年5月至2014年2月任职于Life Technologies Corporation的董事会，该公司是一家上市医疗设备公司，2009年8月至2015年3月被出售给Becton Dickinson和Invuity，Inc.从2014年10月到2018年10月出售给Stryker。Lucier先生在宾夕法尼亚州立大学（Pennsylvania State University）获得工业工程学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Gregory Lucier has served as a member of our board of directors since June 2020. Mr. Lucier has served as the Chief Executive Officer of Corza Health, Inc., a privately-held company focused on acquiring companies and assets as part of a strategy to build a market-leading healthcare business, since April 2019. Prior to that, he served as Chief Executive Officer of NuVasive, Inc., a publicly-traded medical device company, from June 2015 to December 2018. Before joining Nuvasive, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation formerly Invitrogen Corporation, a publicly-traded global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is Chairman of the boards of directors of Nuvasive, Inc., a publicly traded medical device company, and Epic Sciences, a privately-held biotechnology company, and has served as a director of Catalent, Inc., a publicly-traded pharmaceutical company, since April 2015 and previously served on the boards of directors of Life Technologies Corporation from May 2003 to February 2014 of CareFusion Corporation, a publicly-traded medical device company, from August 2009 until its sale to Becton Dickinson in March 2015 and of Invuity, Inc. from October 2014 until its sale to Stryker in October 2018. Mr. Lucier received his B.S. in Industrial Engineering from Pennsylvania State University and his M.B.A. from Harvard Business School.
- Louise Makin
-
Louise Makin是Intertek Group plc和Theramex Group的非执行董事，Theramex Group是一家专注于女性健康的制药公司，1851信托的主席，拓展信托的受托人，剑桥大学圣约翰学院的荣誉院士。Makin博士于2004年10月至2019年8月担任BTG plc的首席执行官，领导BTG从1.5亿美元的价值转型，以42亿美元的价格被Boston Scientific收购，成功收购八家公司并将其整合到BTG中，以创建领先的介入医学业务。任职BTG公司之前，她曾任职Baxter梦百合公司（始于2000年），担任欧洲战略和业务发展Vice President（始于2001年），在那里她曾担任Baxter梦百合公司的欧洲生物制药总裁，在那里她负责欧洲、非洲和中东事务。2015年1月至2019年10月，Makin博士在伍德福德患者资本信托公司（Woodford Patient Capital Trust plc）任职，在那里她曾担任审计和管理参与委员会成员。她也曾担任English China Clay公司的全球陶瓷董事，并于1985年至1998年在ICI公司开始她的职业生涯，担任多种职务。Makin博士拥有英国米尔顿凯恩斯（Milton Keynes）开放大学的工商管理硕士学位，以及剑桥大学（Cantab）材料科学硕士和博士学位。
Louise Makin is a non-executive director of Intertek Group plc and Theramex Group, a Pharmaceutical Company focused on women’s health, Chair of the 1851 Trust, a Trustee of the Outward Bound Trust, and an Honorary Fellow of St. John’s College, Cambridge. Dr. Makin was Chief Executive Officer of BTG plc from October 2004 to August 2019 where she led the transformation of BTG from $150 million in value, to its acquisition by Boston Scientific for $4.2 billion by successfully acquiring and integrating eight companies into BTG to create a leading Interventional Medicine Business. Prior to BTG, she was at Baxter Healthcare from 2000 first as Vice President, Strategy & Business Development Europe then from 2001 she was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East. From January 2015 to October 2019 Dr. Makin was at Woodford Patient Capital Trust plc, where she served on the Audit and Management Engagement Committees. She also served as Director of Global Ceramics at English China Clay, and started her career at ICI serving in a variety of roles between 1985 and 1998. Dr. Makin has an MBA from the Open University in Milton Keynes, England, and an MA and PhD in Material Sciences from the University of Cambridge (Cantab). - Louise Makin是Intertek Group plc和Theramex Group的非执行董事，Theramex Group是一家专注于女性健康的制药公司，1851信托的主席，拓展信托的受托人，剑桥大学圣约翰学院的荣誉院士。Makin博士于2004年10月至2019年8月担任BTG plc的首席执行官，领导BTG从1.5亿美元的价值转型，以42亿美元的价格被Boston Scientific收购，成功收购八家公司并将其整合到BTG中，以创建领先的介入医学业务。任职BTG公司之前，她曾任职Baxter梦百合公司（始于2000年），担任欧洲战略和业务发展Vice President（始于2001年），在那里她曾担任Baxter梦百合公司的欧洲生物制药总裁，在那里她负责欧洲、非洲和中东事务。2015年1月至2019年10月，Makin博士在伍德福德患者资本信托公司（Woodford Patient Capital Trust plc）任职，在那里她曾担任审计和管理参与委员会成员。她也曾担任English China Clay公司的全球陶瓷董事，并于1985年至1998年在ICI公司开始她的职业生涯，担任多种职务。Makin博士拥有英国米尔顿凯恩斯（Milton Keynes）开放大学的工商管理硕士学位，以及剑桥大学（Cantab）材料科学硕士和博士学位。
- Louise Makin is a non-executive director of Intertek Group plc and Theramex Group, a Pharmaceutical Company focused on women’s health, Chair of the 1851 Trust, a Trustee of the Outward Bound Trust, and an Honorary Fellow of St. John’s College, Cambridge. Dr. Makin was Chief Executive Officer of BTG plc from October 2004 to August 2019 where she led the transformation of BTG from $150 million in value, to its acquisition by Boston Scientific for $4.2 billion by successfully acquiring and integrating eight companies into BTG to create a leading Interventional Medicine Business. Prior to BTG, she was at Baxter Healthcare from 2000 first as Vice President, Strategy & Business Development Europe then from 2001 she was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East. From January 2015 to October 2019 Dr. Makin was at Woodford Patient Capital Trust plc, where she served on the Audit and Management Engagement Committees. She also served as Director of Global Ceramics at English China Clay, and started her career at ICI serving in a variety of roles between 1985 and 1998. Dr. Makin has an MBA from the Open University in Milton Keynes, England, and an MA and PhD in Material Sciences from the University of Cambridge (Cantab).
- Greg Summe
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- John Carethers
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Joseph Massaro
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Lan Kang
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Mala Murthy
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Emmanuel Ligner
-
Emmanuel Ligner，于2024年3月至2025年3月担任Cerba HealthCare首席执行官。在此之前，Ligner先生于2020年4月至2024年3月期间担任Cytiva总裁兼首席执行官以及丹纳赫公司的集团高管。Ligner先生还曾于2008年4月至2020年4月在GE Healthcare担任多个职务，包括生命科学总裁兼首席执行官。Ligner先生于1996年作为大冢制药的医疗代表开始了他在生物制药领域的职业生涯，后来在Abbott Diagnostics和Whatman International担任过各种职务。Ligner先生拥有威尔士大学学院市场营销学士学位和萨瓦大学商业MBA学位。
Emmanuel Ligner,served as Chief Executive Officer of Cerba HealthCare from March 2024 to March 2025. Prior to that, Mr. Ligner served as President and Chief Executive Officer of Cytiva and a Group Executive of Danaher Corporation from April 2020 to March 2024. Mr. Ligner also served in several roles at GE HealthCare from April 2008 to April 2020, including President and Chief Executive Officer, Life Sciences. Mr. Ligner began his career in biopharma as a Medical Representative at Otsuka Pharmaceutical in 1996, later serving in various roles at Abbott Diagnostics and at Whatman International. Mr. Ligner holds a B.A. in Marketing from University College of Wales and an MBA in Commerce from Université de Savoie. - Emmanuel Ligner，于2024年3月至2025年3月担任Cerba HealthCare首席执行官。在此之前，Ligner先生于2020年4月至2024年3月期间担任Cytiva总裁兼首席执行官以及丹纳赫公司的集团高管。Ligner先生还曾于2008年4月至2020年4月在GE Healthcare担任多个职务，包括生命科学总裁兼首席执行官。Ligner先生于1996年作为大冢制药的医疗代表开始了他在生物制药领域的职业生涯，后来在Abbott Diagnostics和Whatman International担任过各种职务。Ligner先生拥有威尔士大学学院市场营销学士学位和萨瓦大学商业MBA学位。
- Emmanuel Ligner,served as Chief Executive Officer of Cerba HealthCare from March 2024 to March 2025. Prior to that, Mr. Ligner served as President and Chief Executive Officer of Cytiva and a Group Executive of Danaher Corporation from April 2020 to March 2024. Mr. Ligner also served in several roles at GE HealthCare from April 2008 to April 2020, including President and Chief Executive Officer, Life Sciences. Mr. Ligner began his career in biopharma as a Medical Representative at Otsuka Pharmaceutical in 1996, later serving in various roles at Abbott Diagnostics and at Whatman International. Mr. Ligner holds a B.A. in Marketing from University College of Wales and an MBA in Commerce from Université de Savoie.
高管简历
中英对照 | 中文 | 英文- Christophe Couturier
Christophe Couturier是我们服务执行Vice President，他自2018年4月以来一直担任该职位。在加入Avantor之前，Couturier先生于2017年9月至2018年4月担任个人咨询公司Salicornia，LLC的首席执行官，并于2016年9月至2017年7月担任生物技术公司Ovascience的首席财务官。任职Ovascience公司之前，他曾任职Millipore Sigma公司（生命科学和高技术公司）12年以上，在那里他曾担任多种服务、合并整合、综合管理、财务和咨询职务。
Christophe Couturier is Executive Vice President, AMEA, a position he has held since April 2021. Prior to his current role, Mr. Couturier served as Executive Vice President, Services, from April 2018 to April 2021. Prior to joining Avantor, Mr. Couturier served as Chief Executive Officer of Salicornia, LLC, a personal consulting company, from September 2017 to April 2018 and, before Salicornia, as Chief Financial Officer at OvaScience, a biotechnology company, from September 2016 to July 2017. Prior to OvaScience, Mr. Couturier spent more than 12 years at Millipore Sigma, a life science and high technology company, where he held a variety of services, merger integration, general management, finance and consulting positions.- Christophe Couturier是我们服务执行Vice President，他自2018年4月以来一直担任该职位。在加入Avantor之前，Couturier先生于2017年9月至2018年4月担任个人咨询公司Salicornia，LLC的首席执行官，并于2016年9月至2017年7月担任生物技术公司Ovascience的首席财务官。任职Ovascience公司之前，他曾任职Millipore Sigma公司（生命科学和高技术公司）12年以上，在那里他曾担任多种服务、合并整合、综合管理、财务和咨询职务。
- Christophe Couturier is Executive Vice President, AMEA, a position he has held since April 2021. Prior to his current role, Mr. Couturier served as Executive Vice President, Services, from April 2018 to April 2021. Prior to joining Avantor, Mr. Couturier served as Chief Executive Officer of Salicornia, LLC, a personal consulting company, from September 2017 to April 2018 and, before Salicornia, as Chief Financial Officer at OvaScience, a biotechnology company, from September 2016 to July 2017. Prior to OvaScience, Mr. Couturier spent more than 12 years at Millipore Sigma, a life science and high technology company, where he held a variety of services, merger integration, general management, finance and consulting positions.
- James Bramwell
James Bramwell是我们的战略合作伙伴执行Vice President，他自2017年11月以来一直担任该职位。在担任现职之前，布拉姆韦尔先生曾于2016年3月至2017年11月担任VWR战略合作伙伴和全球出口高级副总裁，。从2008年6月到2016年3月，布拉姆韦尔担任VWR&；8217；S的高级副总裁，战略合作伙伴。
James Bramwell is Executive Vice President, Strategic Partners, a position he has held since November 2017. Prior to his current role, Mr. Bramwell served as Senior Vice President, Strategic Partners and Global Export of VWR, a position he held from March 2016 to November 2017. From June 2008 until March 2016 Mr. Bramwell served as VWR's Senior Vice President, Strategic Partners.- James Bramwell是我们的战略合作伙伴执行Vice President，他自2017年11月以来一直担任该职位。在担任现职之前，布拉姆韦尔先生曾于2016年3月至2017年11月担任VWR战略合作伙伴和全球出口高级副总裁，。从2008年6月到2016年3月，布拉姆韦尔担任VWR&；8217；S的高级副总裁，战略合作伙伴。
- James Bramwell is Executive Vice President, Strategic Partners, a position he has held since November 2017. Prior to his current role, Mr. Bramwell served as Senior Vice President, Strategic Partners and Global Export of VWR, a position he held from March 2016 to November 2017. From June 2008 until March 2016 Mr. Bramwell served as VWR's Senior Vice President, Strategic Partners.
- Emmanuel Ligner
Emmanuel Ligner，于2024年3月至2025年3月担任Cerba HealthCare首席执行官。在此之前，Ligner先生于2020年4月至2024年3月期间担任Cytiva总裁兼首席执行官以及丹纳赫公司的集团高管。Ligner先生还曾于2008年4月至2020年4月在GE Healthcare担任多个职务，包括生命科学总裁兼首席执行官。Ligner先生于1996年作为大冢制药的医疗代表开始了他在生物制药领域的职业生涯，后来在Abbott Diagnostics和Whatman International担任过各种职务。Ligner先生拥有威尔士大学学院市场营销学士学位和萨瓦大学商业MBA学位。
Emmanuel Ligner,served as Chief Executive Officer of Cerba HealthCare from March 2024 to March 2025. Prior to that, Mr. Ligner served as President and Chief Executive Officer of Cytiva and a Group Executive of Danaher Corporation from April 2020 to March 2024. Mr. Ligner also served in several roles at GE HealthCare from April 2008 to April 2020, including President and Chief Executive Officer, Life Sciences. Mr. Ligner began his career in biopharma as a Medical Representative at Otsuka Pharmaceutical in 1996, later serving in various roles at Abbott Diagnostics and at Whatman International. Mr. Ligner holds a B.A. in Marketing from University College of Wales and an MBA in Commerce from Université de Savoie.- Emmanuel Ligner，于2024年3月至2025年3月担任Cerba HealthCare首席执行官。在此之前，Ligner先生于2020年4月至2024年3月期间担任Cytiva总裁兼首席执行官以及丹纳赫公司的集团高管。Ligner先生还曾于2008年4月至2020年4月在GE Healthcare担任多个职务，包括生命科学总裁兼首席执行官。Ligner先生于1996年作为大冢制药的医疗代表开始了他在生物制药领域的职业生涯，后来在Abbott Diagnostics和Whatman International担任过各种职务。Ligner先生拥有威尔士大学学院市场营销学士学位和萨瓦大学商业MBA学位。
- Emmanuel Ligner,served as Chief Executive Officer of Cerba HealthCare from March 2024 to March 2025. Prior to that, Mr. Ligner served as President and Chief Executive Officer of Cytiva and a Group Executive of Danaher Corporation from April 2020 to March 2024. Mr. Ligner also served in several roles at GE HealthCare from April 2008 to April 2020, including President and Chief Executive Officer, Life Sciences. Mr. Ligner began his career in biopharma as a Medical Representative at Otsuka Pharmaceutical in 1996, later serving in various roles at Abbott Diagnostics and at Whatman International. Mr. Ligner holds a B.A. in Marketing from University College of Wales and an MBA in Commerce from Université de Savoie.
- Brittany Hankamer
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Steven W. Eck
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- R. Brent Jones
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Claudius Sokenu
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Kitty Sahin
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Benoit Gourdier
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介